Oculis (OCS) to Release Earnings on Thursday

Oculis (NASDAQ:OCS) is set to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Oculis to post earnings of ($0.52) per share for the quarter.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). The company had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Price Performance

OCS opened at $17.56 on Wednesday. The firm has a market cap of $711.18 million, a price-to-earnings ratio of -9.15 and a beta of -0.16. Oculis has a fifty-two week low of $9.60 and a fifty-two week high of $18.00. The company’s 50-day moving average price is $13.73 and its 200 day moving average price is $12.51. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Oculis in a research note on Wednesday, October 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $29.20.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.